US › Healthcare

Harvard Bioscience Inc (HBIO)

US · Healthcare · Medical Instruments & Supplies

$8.03+0.75%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$22.7M

Revenue YoY

+11.1%

Net profit

$-2.9M

EPS

$-0.22

EPS estimate

$-0.21

Net margin

-12.8%

EPS came in at -0.22 against a street estimate of -0.21 — a miss of 4.8%.

Key statistics

Market cap

$36.8M

Forward P/E

15.1

P/B

4.92

Book value

$1.63

EPS (TTM)

$-2.30

52-week high

$9.40

52-week low

$3.75

50-day MA

$6.78

200-day MA

$6.23

Beta

1.53

Analyst view

Analysts rate Harvard Bioscience Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $7.50.

Shareholding

Insiders

9.40%

Institutions

43.37%

Largest institutional holders

Fund	Stake
Weber Capital Management LLC	6.83%
Acadian Asset Management LLC	3.95%
Vanguard Capital Management, LLC	3.59%
Corsair Capital Management LLC	2.74%
Meros Investment Management, LP	2.60%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	2.58%
Two Sigma Investments LLC	2.51%
Renaissance Technologies Corp	2.23%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Harvard Bioscience Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.